Literature DB >> 12455046

Polycystic kidney and renal cell carcinoma in Japanese and Chinese toad hybrids.

Prince Masahito1, Midori Nishioka, Yasuyuki Kondo, Ieharu Yamazaki, Kimie Nomura, Yo Kato, Haruo Sugano, Tomoyuki Kitagawa.   

Abstract

Frequent development of renal cell carcinomas in hybrids between Japanese toads (Bufo japonicus) and imported Chinese toads (Bufo raddei) was first reported by 2 of our authors in 1987. Such renal tumors of toads had never been observed previously in the laboratory. To confirm the observation and to establish a new animal model system, hybrids between female Japanese and male Chinese toads were newly generated from 3 pairs of parents and pathological changes in their kidneys were examined sequentially over 6 years. In hybrids from 2 of the 3 pairs, bilateral polycystic kidney developed at a high frequency from 3 months after fertilization, this being associated with the emergence of atypical, premalignant-appearing cells in proximal tubules. Papillary lesions developed after 12 months and renal cell carcinomas after 48 months. Such pathological changes were never seen in non-hybrid Chinese or Japanese toads. Electron microscopy showed no evidence of any viral participation. This unique toad model may prove useful for investigation of the underlying mechanisms of genetically determined renal cell carcinogenesis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12455046     DOI: 10.1002/ijc.10774

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

Review 1.  Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates.

Authors:  Jacques Robert
Journal:  Dev Comp Immunol       Date:  2010-06-02       Impact factor: 3.636

2.  Pathologic Lesions of the Budgett Frog (Lepidobatrachus laevis), an Emerging Laboratory Animal Model.

Authors:  Mandy A Womble; Gregory A Lewbart; Heather R Shive
Journal:  Comp Med       Date:  2020-03-31       Impact factor: 0.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.